US EditionCaris Life Sciences Files Registration Statement for Proposed Initial Public Offering
- On May 23, 2025, Caris Life Sciences submitted a Form S-1 registration statement with the SEC from its headquarters in Irving, Texas, seeking to offer shares of its Class A common stock in a public listing on the Nasdaq Global Select Market.
- Caris submitted the filing to the SEC to list shares under ticker symbol CAI but has not determined the number of shares or price range for the offering.
- Caris is a patient-centric, next-generation AI TechBio company applying molecular profiling and machine learning to develop advanced precision medicine solutions.
- The company leverages whole exome and transcriptome sequencing alongside a large clinico-genomic database to provide diagnostic tools for detection, monitoring, and therapy selection.
- The registration statement is not yet effective, and sales or offers of securities cannot occur before SEC approval or in unlawful jurisdictions.
42 Articles
42 Articles
Denton Record-Chronicle
Caris Life Sciences Files Registration Statement for Proposed Initial Public Offering
IRVING, Texas, May 23, 2025 /PRNewswire/ -- Caris Life Sciences® ("Caris"), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange…
Caris Life Sciences Files Registration Statement for Proposed Initial Public Offering - PressReach
IRVING, Texas, May 23, 2025 /PRNewswire/ — Caris Life Sciences® (“Caris”), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its Class A common stock. The number of shares to be offered and the price range for the proposed off…
Caris Life Sciences discloses rise in revenue in US IPO filing - Regional Media News
(Reuters) -Biotech company Caris Life Sciences filed its paperwork to go public in the U.S. on Friday as the stock market shows signs of recovery after tariff shocks. Irving, Texas-based firm reported a revenue rise to $412.3 million in 2024 compared with $306.1 million in 2023, according to the regulatory filing. Activity in the U.S. IPO market had declined after a strong start in 2025 due to an ever-evolving tariff environment, geopolitical un…
Coverage Details
Bias Distribution
- 73% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
